QGEN

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Qiagen NV revenue for the last quarter amounts to 532.58M USD, increased 6.12 % YoY.

Qiagen NV. EPS for the last quarter amounts to 0.60 USD, increased 33.33 % YoY.

Qiagen NV (QGEN) has 5765 emplpoyees as of January 10 2026.

Today QGEN has the market capitalization of 9.99B USD.